The formation of Hope Therapeutics and the re-designation of NRX-100 to HTX-100 represent strategic moves to focus on a promising treatment for suicidal depression. By offering shares and a royalty coupon to current shareholders, NRx Pharmaceuticals is directly rewarding its investors and potentially increasing the stock's attractiveness. The structuring of this transaction to avoid taxation for shareholders further enhances its appeal. Given the focus on a significant healthcare need, this development could positively impact NRXP's stock in the short term, assuming market reception of the treatment's potential and the financial structuring is favorable.